David Leary

Rose’s Dad, golfer, salesman

[Neurocrine Biosciences @neurocrine]

Today we announced the initiation of a Phase 1 clinical study evaluating NBIP-‘1968, our internally discovered investigational therapy for obesity.

NBIP-‘1968 is a long-acting triple agonist designed to target the GLP-1, GIP, and glucagon receptors - key pathways involved in appetite regulation, energy balance, and glycemic control.

This milestone marks an important step in advancing our growing metabolic disease portfolio and reflects our commitment to developing differentiated therapies for people living with obesity.

https://t.co/pLsuAQQ9Kn

[Neurocrine Biosciences @neurocrine]

We recently shared our Q2 2026 financial results, highlighting the strength of our commercial portfolio and the progress of our clinical pipeline.

Read more here: https://t.co/HYO5hnwWC1

[Neurocrine Biosciences @neurocrine]

Today, we announced our Q2 2026 financial results. During our earnings call, Chief Executive Officer Kyle Gano discussed how Neurocrine’s three first-in-class medicines are funding one of the industry’s strongest late-state neuroscience pipelines as we focus on helping people living with serious, under-addressed diseases.

Read more in our earnings press release: https://t.co/9zJpGxhpcO

[Neurocrine Biosciences @neurocrine]

Neurocrine Chief Financial Officer Matt Abernethy was recently featured in @CNBC Cures, where he shared the personal journey that helped bring him to Neurocrine.

As a father of a son living with classic congenital adrenal hyperplasia, a rare endocrine disorder, Matt understands firsthand the challenges families face and the hope they hold for new treatment options. His story highlights the powerful connection between personal experience, purpose-driven leadership and the pursuit of scientific innovation.

We are grateful for leaders like Matt who share their experiences and remind us why advancing science for patients and families matters.

https://t.co/aqRXtxG5lN

[Neurocrine Biosciences @neurocrine]

Wishing everyone a joyful holiday season! We’re thankful for our Neurocrine team and the patients and communities we serve. https://t.co/sZdQhgaFVI

[Neurocrine Biosciences @neurocrine]

With history that spans more than three decades, we have some stories to share.
Our new web page, Brave Science: Stories of Discovery and Dedication, features videos from our leaders, as well as in-depth timelines about our treatments for tardive dyskinesia and congenital adrenal hyperplasia. Explore the page and view how our commitment to developing potential life-changing treatments for patients with great needs has never wavered: https://t.co/6ilBJ0PXDr

[Neurocrine Biosciences @neurocrine]

Today is World Movement Disorders Day, and we’re raising awareness for the many people living with involuntary movement disorders, such as tardive dyskinesia and chorea associated with Huntington’s Disease. #MoveDisorder

[Neurocrine Biosciences @neurocrine]

Happy Thanksgiving from all of us at Neurocrine Biosciences! We hope you have a wonderful and restful holiday.

[Neurocrine Biosciences @neurocrine]

November 11 is Veteran’s Day and we’re recognizing the brave people who have served in our military. We are spotlighting Vice President of Quality Assurance Chance Powell who shares what Veteran’s Day means to him.

[Neurocrine Biosciences @neurocrine]

We honor National Native American Heritage Month by celebrating the rich cultures, traditions, and achievements of the Indigenous people throughout history and today. #NativeAmericanHeritageMonth

[Neurocrine Biosciences @neurocrine]

#FromInterntoFullTime: Meet Davis Arca, the analytical development team’s newest addition! The invaluable skills that Davis learned during his internship have prepared him for the next step in his career here at Neurocrine. Welcome, Davis!

[Neurocrine Biosciences @neurocrine]

#FromInterntoFullTime: Meet Jacob Novak, who recently joined the cyber security team following this summer’s internship. As an intern, Jacob was able to gain experiences he wouldn’t have received with education alone. Welcome, Jacob!

[Neurocrine Biosciences @neurocrine]

We welcomed students from @cdrewu for a day of exploration and connection. Students toured our labs, networked with early career professionals from our research and development teams, and participated in a resume workshop.

Thank you to all who made the event happen. We hope to keep inspiring the next generation of science leaders!

[Neurocrine Biosciences @neurocrine]

We have been recognized on the 2025 Fortune Best Workplaces for Parents™ list. This recognition reinforces our commitment to helping employees grow their careers while raising their families. https://t.co/TMzqZezl9o
#BestWorkplacesforParents

[Neurocrine Biosciences @neurocrine]

November 9 – 15 is National Nurse Practitioner Week. At Neurocrine, we recognize the contributions made by nurse practitioners (NPs) and the unique role they play in patient care, including those dealing with mental health challenges. NPs are valuable contributors to the mental health care system, helping enhance the delivery of high-quality, comprehensive care to individuals in need.

[Neurocrine Biosciences @neurocrine]

We’re honored to be a sponsor of Adrenal Insufficiency United’s Cortisol Summit being held November 7-8 in Phoenix. Neurocrine is committed to supporting patients, their caregivers, and families who are affected by adrenal insufficiency. Learn more: https://t.co/DCQIGLd7OF

[Neurocrine Biosciences @neurocrine]

We’re going all in and joining the @EpilepsyFdn to raise awareness for #NationalEpilepsyAwarenessMonth. Being all in means taking action in big and small ways. Let’s start the dialogue, share stories and drive change. Get involved: https://t.co/vFO3dcFab0 #NEAM

[Neurocrine Biosciences @neurocrine]

At @PsychCongress 2025, we presented new qualitative study findings from interviews and focus groups that offer insight into the functional outcome priorities of patients with schizophrenia, caregivers, and prescribers.

Twenty-six functional outcome concepts were included across four domains, including activities of daily living, self-care/appearance/health, relationships/communication and social/leisure.

Patients prioritized functional outcomes in the activities of daily living domain, such as doing chores and maintaining a job, while caregivers and prescribers prioritized the self-care/appearance/health domain, which includes medication adherence, attending appointments and personal hygiene.

These findings regarding the relative importance of various functional outcomes should be considered when developing novel treatments and care strategies for this serious condition.

Check out our pipeline to see what we’re working on: https://t.co/GHH7EmB7gd #PsychCongress2025

[Neurocrine Biosciences @neurocrine]

Newborn Screening Awareness Month is recognized each September. Newborn screening is performed in the first few days of life and involves simple tests that can detect genetic, hormonal, and metabolic disorders that might not be apparent at birth. This screening can identify infants who may have certain conditions that could be life threatening, like congenital adrenal hyperplasia.

[Neurocrine Biosciences @neurocrine]

Neurocrine was proud to be a part of the San Diego Food Bank’s Drive Out Hunger Golf Classic earlier this month. Proceeds from the tournament support the Food Bank’s critical hunger-relief programs, including the Food 4 Kids Backpack Program, which provides weekend packages of food to elementary school children who face chronic hunger when free school meals are unavailable. Our Chief Financial Officer Matt Abernethy, who serves on the Food Bank’s Board of Directors, shares why this cause is so important to all of us at Neurocrine in this interview with @KUSINews : https://t.co/2Kxx1jBecY